

PRESS RELEASE

NOTIFICATION PURSUANT TO ARTICLE 17 OF THE AIM ITALIA ISSUERS REGULATIONS

Pisa, 28th May 2019 – Pharmanutra S.p.A (“PHN”) hereby states, in accordance with legislation on Transparency and Article 17 of the AIM Italia Issuer Regulations, to have received on this day notification from Karios Partners SGR S.p.A that the materiality threshold equal to 5% of the PHN share capital was exceeded on 24th May 2019.

Specifically, the above shareholder declares to hold, as part of their collective asset management activities, 499,259 PHN ordinary shares, equal to 5.16% of the relative share capital.

On the basis of the notification received from the shareholders and the information currently available to the Company, the shareholders that hold a stake of over 5% of the share capital with PHN voting rights are therefore the following:

SHAREHOLDER	OWNERSHIP TITLE	NUMBER OF SHARES WITH VOTING RIGHTS HELD	% ON THE SHARE CAPITAL WITH VOTING RIGHT
Andrea Lacorte	Owner	3,118,334 ⁽¹⁾	32.21
Roberto Lacorte	Owner	2,318,833 ⁽²⁾	23.95
Beda S.r.l. ⁽³⁾	Owner	1,094,993	11.31
Kairos Partners SGR S.p.A.	Discretionary Asset Management	499,259	5.16

⁽¹⁾ Of which 950,000 PHN ordinary shares are held through the trust company COFIRCONT Compagnia Fiduciaria S.r.l pursuant to a specific fiduciary mandate.

⁽²⁾ Of which 950,000 PHN ordinary shares are held through the trust company COFIRCONT Compagnia Fiduciaria S.r.l pursuant to a specific fiduciary mandate.

⁽³⁾ It should be noted that Carlo Volpi is sole shareholder and sole director of Beda S.r.l.

It is notified that, in compliance with the article 26 of the AIM Italia Issuer Regulations, the names of the PHN major shareholders are also available on the company’s website (www.pharmanutra.it / Section “Investors - Capitale Sociale e Azionariato”).

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated with a wealth of scientific evidence, with 91 studies published involving more than 6000 subjects. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 150 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 49 countries abroad, through 33 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL brand, where it boasts a number of important patents on sucrosomial technology. Over the years, the Group has developed a precise

strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

<http://www.PharmaNutra.it>

For Information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b

56122 Pisa

Tel. +39 050 7846500

Fax +39 050 7846524

investorrelation@PharmaNutra.it

Nomad & Specialist

CFO SIM S.p.A.

Via dell'Annunciata 23/4

20121 Milan

Tel. +39 02 303431

ecm@cfosim.com

Press Office

Spriano Communication&Partners

Tel. +39 02 83635708

Matteo Russo - Cristina Tronconi

Mob. +39 347 9834881 +39 346 0477901

mrusso@sprianocommunication.com

ctronconi@sprianocommunication.com